All In MedTech

FDA Clearance Tracker · P240024

Genio® System 2.1

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 19, 2026Latest source record: Aug 8, 2025 (this decision)Source: openFDAMethods & limitations

PMA

Decided

Aug 8, 2025

Approved

Time to decision

403 days

Received Jul 1, 2024. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA

Device class

Class III

The decision

FDA number
P240024
Device name
Genio® System 2.1
Applicant
Nyxoah S.A.
Applicant location
Mont-Saint-Guibert
Received
Jul 1, 2024
Decided
Aug 8, 2025
Decision
Approved
Supplements
4 in FDA's data for this PMA. See them on the FDA record

Device type

Device class
Class III

Every decision under product code MNQ

FDA's approval statement

As written in FDA's record.

Approval for The Nyxoah Genio System 2.1, which includes the Implantable Stimulator Model #2954, Surgical Template, External Stimulator, Disposable Patch, Activation Chip Model #2364, Charging Unit Model #2238, Sleep Lab Application, Repeater, and Smartphone Application. It is indicated for use in the treatment of moderate to severe Obstructive Sleep Apnea (OSA) (apnea-hypopnea index [AHI] of greater than or equal to 15 and less than or equal to 65). The device is intended for adult patients 22 years of age and older who have been confirmed to fail, cannot tolerate or are ineligible to be treated with current standard of care treatments including lifestyle modifications, positive airway pressure (PAP) treatments (such as continuous positive airway pressure [CPAP] or bi-level positive airway pressure [BiPAP] machines), oral appliances (such as mandibular advancement devices), and pharmacotherapy (such as tirzepatide). PAP failure is defined as an inability to eliminate OSA (residual AHI of greater than 15 despite PAP usage), and PAP intolerance is defined as: 1. Inability to use PAP (at least 5 nights per week of usage; usage defined as greater than 4 hours of use per night), or 2. Unwillingness to use PAP (PAP therapy initiated and subsequently discontinued by choice).

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • It is not the first decision under product code MNQ. The earliest in FDA's data is P130008, decided Apr 30, 2014.
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

Other decisions for Nyxoah S.A.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

No other decisions since 2015 under this exact applicant name.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.